GeoVax Advances GEO-MVA Phase 3 Trial, Reports Q1 2026 Results

GeoVax Labs, Inc. (Nasdaq: GOVX) has released its first quarter 2026 financial results and provided a business update, emphasizing progress on its lead vaccine candidate GEO-MVA for mpox and smallpox. The company is advancing a Phase 3 immunobridging study under an expedited regulatory pathway aligned with the European Medicines Agency (EMA). CEO David A. Dodd highlighted the strategic importance of GEO-MVA in addressing global orthopoxvirus vaccine supply constraints and reducing dependence on a single foreign supplier. The trial is expected to enroll approximately 500 participants and aims to demonstrate non-inferiority to an approved MVA comparator vaccine. GeoVax has completed cGMP manufacturing and selected a CRO, positioning GEO-MVA as a potential additional source of MVA-based vaccine supply for public health preparedness and biodefense.

Alongside its infectious disease focus, GeoVax is advancing Gedeptin, its gene-directed enzyme prodrug therapy (GDEPT) platform for immuno-oncology. The company recently strengthened its intellectual property through an exclusive license agreement with Emory University covering Gedeptin in combination with immune checkpoint inhibitors. This strategy aims to convert immunologically 'cold' tumors into responsive microenvironments, enhancing the efficacy of PD-1-based therapies. GeoVax believes Gedeptin's mechanism may have broad applicability across solid tumors, particularly those resistant to checkpoint inhibitors. The company is exploring combination strategies in head and neck cancer, including neoadjuvant and first-line settings.

Financially, GeoVax reported a net loss of $5.3 million for Q1 2026, similar to the prior year's $5.4 million loss. Revenue decreased due to the termination of a BARDA contract for its COVID-19 vaccine program. Research and development expenses were $3.9 million, down from $5.4 million, reflecting lower costs from discontinued activities. Cash stood at $1.3 million as of March 31, 2026. The company is prioritizing capital allocation toward GEO-MVA, given its clear regulatory path and market demand. For more details, visit www.geovax.com.